Nocimed harnesses the existing power of Magnetic Resonance Spectro-scopy (MRS) for non-invasive, objective quantification of relative chemical differences in tissues applied to assess the relative chemical biomarkers for tissue degeneration and pain. Our focus is to compare relative differences in these degenerative pain biomarkers between lumbar discs in patients receiving MRS exams of those tissues.
Examples of the potential utility of this new information include helping doctors to:
NOCIMED generates this new information merely via a patented post- processor engine that post-processes data acquired via leading commercial high field MR scanners and spectroscopy pulse sequences.
For more information, please contact us at: